Abstract：Objective To observe the efficacy and safety of intravenous thrombolysis with alteplase combined with domestic tirofiban in the treatment of ST-segment elevation acutemyocardial infarction（STEAMI）.M ethods 30 STEAMI patients admitted to our hospital from May 2012 to July 2013 were selected as the conventional group.These patients met theWHO diagnostic criteria，and could receive thrombolytic therapy≤3 hours and underwent coronary angiography（CAG）within 7 days.32 STEAMIpatients admitted to our hospital from September 2013 to November 2014 were selected as the combination group，and was given thrombolysis with alteplase and tirofiban therapy simultaneously.Patients from both groups were additionally given heparin injection via continuous intravenous infusion for 48 hours，ECG，myocardial enzymogram，activated partial thromboplastin time and CAG were recorded.The indicators of coronary recanalization and adverse drug reaction were observed，and the short-term efficacy and safety were evaluated.Results The peak value of CK-MB，peak time of CK-MB，the resolution of ST segment≥50%and in-hospitalmyocardial infarction for a second time between the combination group and the conventional group were not significant difference（P＞0.05）. Therewere significant differences in 5-7 days infarct-related artery（IRA）blood flow＞TIMIgradeⅢand the occurrence of unstable angina within seven days between the two groups（P＜0.05）.Prothrombin time prolongations at 24 h after thrombolysis between the two groups were significantly different（P＜0.05）.Platelet counts and bleeding events between the two groups were no significant difference（P＞0.05）.Conclusion Intravenous thrombolysis combined with domestic tirofiban hydrochloride in the treatment of STEAMI≤3 hours is superior to the conventional thrombolysis group in improving the infarct-related artery TIMI blood flow，the non-occurrence of unstable angina within 7 days，which is not increase the risk of bleeding.
Van de Werf F，Bax J，Betriu A，et al.Managanent of acute myocardial infarction in patients presenting with Persistent ST-segment elevation：the Task Force on the Managanent of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology［J］.Eur Heart J，2008，29（23）：2909-2945.
Take Force on themanagent of ST-segment elevation acute myocardial infarction of the European Sociely of Cardiology（ESC），Steg PG，James SK，et al.ESC guidelines for the management of acutemyocardial infarction in patients presenting with ST-segment elevation［J］.Eur Heart J，2012，33（20）：2569-2619.
［8］
O′Gara PT，Kushner FG，Ascheim DD，et al.2013 ACCF/AHA guideline for the managent of ST-elevation myocardial infarction：a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines［J］.JAm Coll Cardiol，2013，61（4）：e78-e140.
［9］
Peter K，Kohler B，Straub A，et al.Flow monitoring of lycoproteinⅡb/Ⅲa blockade and platelet function in patients with acute myocardial infarction receiving reteplase，abciximab，and ticlopidine continuous platelet inhibition by the combination of abciximab and ticlopidine［J］.Circulation，2000，102（13）：1490-1496.
［10］
Coulter SA，Cannon CP，Ault KA，et al.High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction results from TIMI（thrombolysis in myocardial infarction）14［J］.Circulation，2000，101（23）：2690-2695.
［11］
Kleiman NS.Pharmacokinetics and pharmacodynamics of glycoproteinⅡb/Ⅲa inhibilors［J］.Am Heart J，199，138（4 Pt2）：263-275.
Ortolani P，Marzocchi A，Marrozzini C，et al.Longterm effectiveness of early administration of glycoproteinⅡb/Ⅲa agents to real-world patients undergoing primary percutaneous interventions：results of a registry study in an ST-elevationmyocardial infarction network［J］.EurHeart J，2009，30（1）：33-43.
Hamm CW，Bassand JP，Agewall S，et al.ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation：the task force for the management of acute coronary syndromes（ACS）in patients presenting without persistent ST-segment elevation of the European Society of Cardiology（ESC）［J］.Eur Heart J，2011，32（23）：2999-3054.
京公网安备 11010502046607号